In last trading session, Lexeo Therapeutics Inc (NASDAQ:LXEO) saw 0.46 million shares changing hands with its beta currently measuring 1.88. Company’s recent per share price level of $3.07 trading at $0.1 or 3.37% at ring of the bell on the day assigns it a market valuation of $101.52M. That closing price of LXEO’s stock is at a discount of -535.18% from its 52-week high price of $19.50 and is indicating a premium of 24.43% from its 52-week low price of $2.32. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.62 million shares which gives us an average trading volume of 322.88K if we extend that period to 3-months.
For Lexeo Therapeutics Inc (LXEO), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.14. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.78 in the current quarter.
Lexeo Therapeutics Inc (NASDAQ:LXEO) trade information
Upright in the green during last session for gaining 3.37%, in the last five days LXEO remained trading in the green while hitting it’s week-highest on Friday, 03/14/25 when the stock touched $3.07 price level, adding 4.66% to its value on the day. Lexeo Therapeutics Inc’s shares saw a change of -53.34% in year-to-date performance and have moved 13.70% in past 5-day. Lexeo Therapeutics Inc (NASDAQ:LXEO) showed a performance of -22.28% in past 30-days. Number of shares sold short was 2.43 million shares which calculate 7.83 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 28 to the stock, which implies a rise of 89.04% to its current value. Analysts have been projecting 28 as a low price target for the stock while placing it at a high target of 28. It follows that stock’s current price would drop -812.05% in reaching the projected high whereas dropping to the targeted low would mean a loss of -812.05% for stock’s current value.
In 2025, company’s earnings growth rate is likely to be around 74.84% while estimates for its earnings growth in next 5 years are of 36.87%.
Lexeo Therapeutics Inc (NASDAQ:LXEO)’s Major holders
Insiders are in possession of 1.25% of company’s total shares while institution are holding 106.47 percent of that, with stock having share float percentage of 107.82%. Investors also watch the number of corporate investors in a company very closely, which is 106.47% institutions for Lexeo Therapeutics Inc that are currently holding shares of the company.
On the other hand, Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund and Janus Henderson Global Life Sciences Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 1.23 shares of worth $3.79 million or 3.73% of the total outstanding shares. The later fund manager was in possession of 682.04 shares on Dec 31, 2024 , making its stake of worth around $2.09 million in the company or a holder of 2.06% of company’s stock.
